Back to results
US 2016/0193298 A1Published application
Therapeutic use of vegf-c and ccbe1
AssigneeLaurantis Pharma Oy
InventorsKari ALITALO, Michael JELTSCH, Andrey ANISIMOV
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic methods, uses and compositions comprising CCBE1 and VEGF-C for treating disorders and conditions involving impaired lymphatic system, particularly lymphedema.
Claims13
A composition comprising:
- I) a first component comprising at least one of the group consisting of:
- a) full-length CCBE1,
- b) a fragment of CCBE1 having the ability to cleave full-length VEGF-C,
- c) an amino acid sequence having at least 80% identity to full-length CCBE1 or to said fragment of CCBE1, wherein said amino acid sequence has the ability to cleave full-length VEGF-C, and
- d) a polynucleotide encoding any of a) through c) above;
- and
- II) a second component comprising at least one of the group consisting of:
- e) VEGF-C,
- f) a fragment of VEGF-C having the ability to bind to, and activate VEGFR-2 and/or VEGFR-3,
- g) an amino acid sequence having at least 80% identity to full-length VEGF-C or to said fragment of VEGF-C, wherein said amino acid sequence has the ability to bind to, and activate, VEGFR-2 and/or VEGFR-3, and
- h) a polynucleotide encoding any of e) through g) above.
8 more elements
(canceled)
A method of treating lymphedema by administering to a patient in need thereof:
- I) a first component comprising at least one of the group consisting of:
- a) full-length CCBE1,
- b) a fragment of CCBE1 having the ability to cleave full-length VEGF-C,
- c) an amino acid sequence having at least 80% identity to full-length CCBE1 or to said fragment of CCBE1, wherein said amino acid sequence has the ability to cleave full-length VEGF-C, and
- d) a polynucleotide encoding any of a) through c) above;
- and
- II) a second component comprising at least one of the group consisting of:
- e) V EGF-C,
- f) a fragment of VEGF-C having the ability to bind to and activate VEGFR-2 and/or VEGFR-3,
- g) an amino acid sequence having at least 80% identity to full-length VEGF-C or to said fragment of VEGF-C, wherein said amino acid sequence has the ability to bind to and activate, VEGFR-2 and/or VEGFR-3, and
- h) a polynucleotide encoding any of e) through g) above;
- wherein said first and second compounds are administered simultaneously, separately or sequentially.
9 more elements
Dependencies are inferred from the claim text.